The present disclosure provides a cohort of novel viral genome derived products for use, for example, in medicine, as a medicaments, as expression vectors and as adjuvants. The disclosed viral genome derived products may be derived from members of the Paramyxoviridae Family which contains a wide variety of vertebrate viruses, including mumps, measles and human parainfluenza viruses.

Provided herein are methods of producing and manufacturing iPSCs, such as iPSCs essentially free of exogeneous viral residuals, and RPE cells. Such methods may comprise cell seeding at low density (e.g., single-cell passaging) and/or culturing at elevated temperature.